Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma

Blood

Volumn 119, Issue 1, 2012, Pages 161-169

  Qian, Jianfei ^a   Zheng, Yuhuan ^a   Zheng, Chengyun ^b   Wang, Lijuan ^c   Qin, Hong ^a   Hong, Sungyoul ^a   Li, Haiyan ^a   Lu, Yong ^a   He, Jin ^a   Yang, Jing ^a   Neelapu, Sattva ^a   Kwak, Larry W ^a   Hou, Jian ^d   Yi, Qing ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

^c ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD134 ANTIGEN MONOCLONAL ANTIBODY; CD4 ANTIGEN; CD8 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; DICKKOPF 1 PROTEIN; DNA VACCINE; INTERLEUKIN 10; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1 MONOCLONAL ANTIBODY; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; FEMALE; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR IMMUNITY;

EID: 84862908226     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-07-368472     Document Type: Article

References (50)

1. Barlogie B, Jagannath S, Vesole DH, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood. 1997;89(3):789-793. (Pubitemid 27121271)
2. Bergenbrant S, Yi Q, Osterborg A, et al. Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients. Br J Haematol. 1996;92(4):840-846. (Pubitemid 26109498)
3. Osterborg A, Yi Q, Henriksson L, et al. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood. 1998;91(7):2459-2466. (Pubitemid 28155521)
4. Reichardt VL, Okada CY, Liso A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma-a feasibility study. Blood. 1999; 93(7):2411-2419. (Pubitemid 29153646)
5. Titzer S, Christensen O, Manzke O, et al. Vaccination of multiple myeloma patients with idiotypepulsed dendritic cells: immunological and clinical aspects. Br J Haematol. 2000;108(4):805-816. (Pubitemid 30304514)
6. Yi Q, Desikan R, Barlogie B, Munshi N. Optimizing dendritic cell-based immunotherapy in multiple myeloma. Br J Haematol. 2002;117(2):297- 305.
7. Yi Q. Dendritic cell-based immunotherapy in multiple myeloma. Leuk Lymphoma. 2003;44(12): 2031-2038. (Pubitemid 37369642)
8. Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003;349(26):2483-2494. (Pubitemid 38010074)
9. Krupnik VE, Sharp JD, Jiang C, et al. Functional and structural diversity of the human Dickkopf gene family. Gene. 1999;238(2):301-313. (Pubitemid 29447031)
10. Kohn MJ, Kaneko KJ, DePamphilis ML. DkkL1 (Soggy), a Dickkopf family member, localizes to the acrosome during mammalian spermatogenesis. Mol Reprod Dev. 2005;71(4):516-522. (Pubitemid 40923519)
11. Hall CL, Bafico A, Dai J, Aaronson SA, Keller ET. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res. 2005; 65(17):7554-7560. (Pubitemid 41297224)
12. Yaccoby S, Ling W, Saha R, et al. Inhibition of DKK1 activity is associated with increased osteoblast numbers and bone formation, reduced osteoclast activity and inhibition of tumor growth in the SCID-rab model for primary myeloma [abstract]. Blood (ASH Annual Meeting Abstracts). 2005; 106(11):189a. Abstract 638.
13. Qian J, Xie J, Hong S, et al. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood. 2007;110(5): 1587-1594. (Pubitemid 47443975)
14. Fredriksen AB, Bogen B. Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences. Blood. 2007;110(6): 1797-1805. (Pubitemid 47443890)
15. Qin H, Cha SC, Neelapu SS, et al. Vaccine site inflammation potentiates idiotype DNA vaccineinduced therapeutic T cell-, and not B cell-, dependent antilymphoma immunity. Blood. 2009; 114(19):4142-4149.
16. Donnelly JJ, Friedman A, Martinez D, et al. Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat Med. 1995;1(6):583-587.
17. Qian J, Hong S, Wang S, et al. Myeloma cell linederived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma. Blood. 2009;114(18):3880-3889.
18. Biragyn A, Surenhu M, Yang D, et al. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J Immunol. 2001;167(11):6644- 6653.
19. Masaki H, Tamura M, Kurane I. Induction of cytotoxic T lymphocytes of heterogeneous specificities by immunization with a single peptide derived from influenza A virus. Viral Immunol. 2000;13(1): 73-81. (Pubitemid 30151782)
20. Ait-Oufella H, Herbin O, Bouaziz JD, et al. B cell depletion reduces the development of atherosclerosis in mice. J Exp Med. 207(8):1579-1587.
21. Lutz MB, Kukutsch N, Ogilvie AL, et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods. 1999;223(1): 77-92. (Pubitemid 29096240)
22. Xie J, Qian J, Wang S, Freeman ME 3rd, Epstein J, Yi Q. Novel and detrimental effects of lipopolysaccharide on in vitro generation of immature dendritic cells: involvement of mitogen-activated protein kinase p38. J Immunol. 2003;171(9): 4792-4800. (Pubitemid 37310599)
23. Qian J, Wang S, Yang J, et al. Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96. Clin Cancer Res. 2005;11(24 Pt 1):8808- 8815.
24. Kanai T, Totsuka T, Uraushihara K, et al. Blockade of B7-H1 suppresses the development of chronic intestinal inflammation. J Immunol. 2003; 171(8):4156-4163. (Pubitemid 37238692)
25. Sugamura K, Ishii N, Weinberg AD. Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol. 2004;4(6):420- 431.
26. Takeda I, Ine S, Killeen N, et al. Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells. J Immunol. 2004; 172(6):3580-3589. (Pubitemid 38337939)
27. Bansal-Pakala P, Jember AG, Croft M. Signaling through OX40 (CD134) breaks peripheral T-cell tolerance. Nat Med. 2001;7(8):907-912. (Pubitemid 32756427)
28. Lauritzsen GF, Bogen B. Idiotype-specific, major histocompatibility complex restricted T cells are of both Th1 and Th2 type. Scand J Immunol. 1991; 33(6):647-656.
29. Lauritzsen GF, Weiss S, Bogen B. Anti-tumour activity of idiotype-specific, MHC-restricted Th1 and Th2 clones in vitro and in vivo. Scand J Immunol. 1993;37(1):77-85. (Pubitemid 23020905)
30. Hong S, Qian J, Yang J, Li H, Kwak LW, Yi Q. Roles of idiotype-specific t cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth. Cancer Res. 2008;68(20):8456-8464.
31. Vergati M, Intrivici C, Huen NY, Schlom J, Tsang KY. Strategies for cancer vaccine development. J Biomed Biotechnol. 2010;pii:596432.
32. Biragyn A, Ruffini PA, Leifer CA, et al. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science. 2002;298(5595): 1025-1029. (Pubitemid 35247310)
33. Jahrsdorfer B, Hartmann G, Racila E, et al. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukocyte Biol. 2001;69(1):81-88. (Pubitemid 32095121)
34. Li J, Song W, Czerwinski DK, et al. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol. 2007;179(4):2493-2500.
35. Matzinger P. The danger model: a renewed sense of self. Science. 2002;296(5566):301-305. (Pubitemid 34303674)
36. Speiser DE, Lienard D, Rufer N, et al. Rapid and strong human CD8- T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest. 2005;115(3):739-746. (Pubitemid 40322250)
37. Kochenderfer JN, Simpson JL, Chien CD, Gress RE. Vaccination regimens incorporating CpGcontaining oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from Tcell populations undergoing homeostatic peripheral expansion after BMT. Blood. 2007; 110(1):450-460. (Pubitemid 47026868)
38. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11(11):3887-3895.
39. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7): 1027-1034.
40. Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2(3):261-268. (Pubitemid 33706004)
41. Staveley-O'Carroll K, Sotomayor E, Montgomery J, et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci U S A. 1998;95(3): 1178-1183. (Pubitemid 28124932)
42. Maxwell JR, Weinberg A, Prell RA, Vella AT. Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion. J Immunol. 2000;164(1):107-112. (Pubitemid 30012979)
43. Weinberg AD, Rivera MM, Prell R, et al. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol. 2000;164(4):2160- 2169.
44. Kjaergaard J, Tanaka J, Kim JA, Rothchild K, Weinberg A, Shu S. Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res. 2000;60(19):5514-5521.
45. Pan PY, Zang Y, Weber K, Meseck ML, Chen SH. OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases. Mol Ther. 2002;6(4):528-536. (Pubitemid 35214875)
46. Kjaergaard J, Peng L, Cohen PA, Drazba JA, Weinberg AD, Shu S. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor. J Immunol. 2001;167(11):6669-6677. (Pubitemid 33081606)
47. Morris A, Vetto JT, Ramstad T, et al. Induction of anti-mammary cancer immunity by engaging the OX-40 receptor in vivo. Breast Cancer Res Treat. 2001;67(1):71-80. (Pubitemid 32703390)
48. Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy JD Jr. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood. 2007;109(5):2106-2111. (Pubitemid 46348212)
49. Sato N, Yamabuki T, Takano A, et al. Wnt inhibitor Dickkopf-1 as a target for passive cancer immunotherapy. Cancer Res. 70(13):5326-5336.
50. Fulciniti M, Tassone P, Hideshima T, et al. Anti- DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood. 2009;114(2): 371-379.